skip to main content

    Updated Visitor Guidelines

 

MENU

 

The Importance of Being Flexible

As part of our Next Generation features, meet Paul Swiecicki, M.D. He's a molecular biologist and has launched his own independent lab as a tenure track assistant professor at the Rogel Cancer Center. In January, 2024, he was named inaugural associate medical director for the Oncology Clinical Trials Support Unit (O-CTSU).

Cracking the Code of RNA

As part of our Next Generation features, meet Amanda Garner, Ph.D. The Garner Lab at Rogel is celebrating its 10th year working at one of the final frontiers in drug discovery—the search for and development of RNA-targeted therapeutics for cancer and other diseases.

Uncovering Cancer's Roots in Chromatin

As part of our Next Generation features, meet Abhijit Parolia, Ph.D. He's a molecular biologist and has launched his own independent lab as a tenure track assistant professor at the Rogel Cancer Center.

Zhou gets $2.9M to develop a system to predict outcomes in multiple myeloma

By combining data from MRI scans and clinical tests, University of Michigan Rogel Cancer Center researcher Chuan Zhou, Ph.D., will develop a decision support tool to tailor treatment for individual patients with multiple myeloma. It’s a cancer that’s considered incurable, with survival ranging from less than a year to more than a decade, depending on the extent and aggressiveness of the tumors.

AACR 2024: Rogel Recap of the 2024 AACR Annual Meeting

Highlights from Rogel's presence at the 2024 AACR Annual Meeting

AACR 2024: NextGen Star Abhijit Parolia presents on new protein that drives prostate cancer progression

Abhijit Parolia, M.S., Ph.D., assistant professor of pathology and urology at the University of Michigan Health Rogel Cancer Center, was named at NextGen Star by the American Association of Cancer Research.

AACR 2024: Ljungman speaks on “KLIPP,” a new technique targeting cancer with CRISPR

Mats Ljungman, Ph.D., Rogel researcher and professor of radiation oncology, shared research on KLIPP, a new technique in precision medicine using CRISPR to target weak spots in cancer cells, at the American Association of Cancer Research's Annual Meeting.

AACR 2024: Chinnaiyan presents on possible therapies to target oncogenic transcription factors

Arul Chinnaiyan, M.D., Ph.D., was one of several Rogel researchers to present at the American Association for Cancer Research 2024 Annual Meeting.

Neuroendocrine Tumor Program

Neuroendocrine tumors are rare. Personalized cancer care and innovative treatment shouldn't be. Contact us at 734-647-8902

Pages